Drug Eruption

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 7776 Experts worldwide ranked by ideXlab platform

William A Welton - One of the best experts on this subject based on the ideXlab platform.

Stefan Wohrl - One of the best experts on this subject based on the ideXlab platform.

  • fixed Drug Eruption caused by mefenamic acid a case series and diagnostic algorithms
    Journal Der Deutschen Dermatologischen Gesellschaft, 2011
    Co-Authors: A Handisurya, Katharina Moritz, Elisabeth Riedl, Christina Reinisch, Georg Stingl, Stefan Wohrl
    Abstract:

    Summary Background: Fixed Drug Eruption is a fairly common Drug-induced hypersensitivity reaction of the skin and the mucous membranes, which is characterized by the re-occurrence of the lesion(s) exactly on the previously involved sites after repeated administration. The pathogenetic mechanisms of this site-specificity are not fully elucidated. Patients and Methods: We report on three cases of fixed Drug Eruption, including a non-pigmenting generalized bullous fixed Drug Eruption, caused by mefenamic acid in its pure form. Results and Conclusion: Provocation tests with the assumed causative Drug represent the gold standard for establishing the diagnosis and for identifying the culprit. Advantages and pitfalls of topical and systemic provocation tests as diagnostic approaches are discussed.

Ümit Türsen - One of the best experts on this subject based on the ideXlab platform.

  • Fixed Drug Eruption due to Ornidazole
    2013
    Co-Authors: Belma Türsen, Ümit Türsen, Erdinç Terzi
    Abstract:

    Ornidazole is a nitroimidazole derivative with, anti-trichomoniasis and anti-parasitic properties. Fixed Drug Eruption (FDE) is a common cutaneous reaction by various Drugs. FDE induced by ornidazole has been reported as 4 rd case in English literature. We describe a 40-year-old male patient with ornidazole associated FDE shortly after starting ornidazole therapy for gastroenteritis. Ornidazole therapy was stopped and the patient was treated with topical corticosteroids and systemic antihistamines. The Eruption resolved within five days. The rash returned following ornidazole rechallenge. We propose that FDE is a side-effect of ornidazole.

  • Glutathione S-transferase polymorphisms in patients with Drug Eruption
    Archives of Dermatological Research, 2004
    Co-Authors: Nurcan Aras Ateş, Ümit Türsen, Lülüfer Tamer, Arzu Kanik, Ebru Derici, Bahadır Ercan, Ugur Atik
    Abstract:

    Glutathione S-transferase (GST) enzymes play an important role in Drug metabolism. GST is a multigene family of enzymes involved in the detoxification and in a few instances activation of a wide variety of chemicals. Detoxification features make it plausible to search for GST polymorphism in patients with Drug Eruption. The GSTM (mu), GSTT (theta) and GSTP (pi) have been shown to be polymorphically distributed. The GSTT1, GSTM1 and GSTP1 gene polymorphism were detected using real-time PCR. GSTM1 and GSTT1 null genotypes were found to be associated with an increased risk of Drug Eruption (OR 2.27, 95% CI 1.20–5.21; OR 2.48, 95% CI 1.12–6.39, respectively). No relationship was observed between the null combination of the GSTM1 and GSTT1 genotype polymorphisms and Drug Eruption risk (OR 2.65, 95% CI 0.62–11.25). Our results show that GSTP1 polymorphism is not a significant contributor to Drug Eruption risk. The GSTM1 and GSTT1 gene polymorphisms seem to be associated with the development of Drug Eruption. Further studies may shed additional light on the role of GSTM1, GSTT1 and GSTP1 in Drug Eruption.

  • Fixed Drug Eruption due to tiaprofenic acid
    Journal of Dermatological Treatment, 2002
    Co-Authors: Ümit Türsen, Ali Biçer, Tamer Irfan Kaya, Guliz Ikizoglu
    Abstract:

    Tiaprofenic acid is a propionic acid derivative with analgesic, anti-inflammatory and antipyretic properties. Fixed Drug Eruption induced by tiaprofenic acid has not been reported previously. Described in this paper is a 57-year-old female patient with tiaprofenic acid-associated fixed Drug Eruption, which occurred shortly after starting tiaprofenic acid therapy for her osteoarthritis. Upon establishment of the diagnosis, tiaprofenic acid therapy was stopped and topical corticosteroids and systemic antihistamines were administered. The Eruption resolved, leaving post-inflammatory hyperpigmentation within 5 days. The rash returned folloiwng tiaprofenic acid rechallenge. It is proposed that fixed Drug Eruption is a new side effect of tiaprofenic acid.

Esen Ozkayabayazit - One of the best experts on this subject based on the ideXlab platform.

  • specific site involvement in fixed Drug Eruption
    Journal of The American Academy of Dermatology, 2003
    Co-Authors: Esen Ozkayabayazit
    Abstract:

    Abstract A total of 105 patients with established fixed Drug Eruption (FDE) by oral provocation were evaluated with regard to a Drug-related site involvement. Cotrimoxazole was the leading causative agent (63.8%), followed by naproxen sodium (23.8%), dipyrone (5.7%), oxicams (4.8%) and other rare causes (1.9%). Cotrimoxazole most frequently induced lesions on genital mucosa; naproxen and oxicams on lips; and dipyrone on trunk and extremities. Isolated FDE on male genitalia (n = 16) was exclusively because of cotrimoxazole. A highly significant association could be established between naproxen and FDE on lips (chi-square = 28.3; corrected P = .000002). As this study represents the largest series of patients with naproxen-induced FDE, we would suggest that naproxen should be considered as an important potential cause of FDE on lips.

  • Drug related clinical pattern in fixed Drug Eruption
    European Journal of Dermatology, 2000
    Co-Authors: Esen Ozkayabayazit, Halil Bayazit, Guzin Ozarmagan
    Abstract:

    Fixed Drug Eruption (FDE) is characterized by recurrent well-defined lesions in the same location each time the Drug responsible is taken. Patients often take more than one Drug simultaneously, and they often do not remember which Drug they have taken. So it is almost always a challenge for the physician to find out the offending agent. The aim of this open prospective study is to investigate the presence of a particular clinical pattern [...]

Bradley C Franz - One of the best experts on this subject based on the ideXlab platform.

Drug Eruption - 15 days free trial to Access Experts & Abstracts